BrainChild Bio raises $116M Series A to launch pivotal registrational trial of BCB-276 CAR T therapy for pediatric DIPG
BrainChild Bio, a Seattle Children’s spinout, raised $116 million in Series A funding to support a pivotal registrational trial of BCB-276, an autologous CAR T-cell therapy targeting DIPG in children, with plans to expand into adult CNS tumors including glioblastoma.
More: FinSMEs, Endpoints News, Fierce Biotech, BioSpace, American Chemical Society, GeekWire, WebProNews, BrainChild Bio, Inc.
- FinSMEs: BrainChild Bio Raises $116M Series A to Fund Phase 2 ILLUMINATE Trial of BCB‑276 for DIPG
-
Endpoints News / Kyle LaHucik: BrainChild Bio raises $116M Series A to fund pivotal B7-H3 CAR-T trial for pediatric DIPG
- Also at: Fierce Biotech, BioSpace, American Chemical Society, GeekWire, WebProNews, BrainChild Bio, Inc.